A single-center prospective cohort study to determine efficacy and safety of DOACs in VTE patients with severe inherited thrombophilia
Latest Information Update: 12 Jul 2021
Price :
$35 *
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- 12 Jul 2021 New trial record